FDA Inks Nanotech Agreement With Cancer And Standards Institutes
This article was originally published in The Gray Sheet
Executive Summary
FDA collaboration in the nanotechnology field with two other federal agencies may serve to facilitate premarket reviews for nanotech-based cancer diagnostics and therapeutics